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Abstract
Hypertension is a complex disorder with high prevalence rates all over the world. We conducted the first genome-wide
gene-based association scan for hypertension in a Han Chinese population. By analyzing genome-wide single-nucleotide-
polymorphism data of 400 matched pairs of young-onset hypertensive patients and normotensive controls genotyped with
the Illumina HumanHap550-Duo BeadChip, 100 susceptibility genes for hypertension were identified and also validated
with permutation tests. Seventeen of the 100 genes exhibited differential allelic and expression distributions between
patient and control groups. These genes provided a good molecular signature for classifying hypertensive patients and
normotensive controls. Among the 17 genes, IGF1, SLC4A4, WWOX, and SFMBT1 were not only identified by our gene-based
association scan and gene expression analysis but were also replicated by a gene-based association analysis of the Hong
Kong Hypertension Study. Moreover, cis-acting expression quantitative trait loci associated with the differentially expressed
genes were found and linked to hypertension. IGF1, which encodes insulin-like growth factor 1, is associated with
cardiovascular disorders, metabolic syndrome, decreased body weight/size, and changes of insulin levels in mice. SLC4A4,
which encodes the electrogenic sodium bicarbonate cotransporter 1, is associated with decreased body weight/size and
abnormal ion homeostasis in mice. WWOX, which encodes the WW domain-containing protein, is related to hypoglycemia
and hyperphosphatemia. SFMBT1, which encodes the scm-like with four MBT domains protein 1, is a novel hypertension
gene. GRB14, TMEM56 and KIAA1797 exhibited highly significant differential allelic and expressed distributions between
hypertensive patients and normotensive controls. GRB14 was also found relevant to blood pressure in a previous genetic
association study in East Asian populations. TMEM56 and KIAA1797 may be specific to Taiwanese populations, because they
were not validated by the two replication studies. Identification of these genes enriches the collection of hypertension
susceptibility genes, thereby shedding light on the etiology of hypertension in Han Chinese populations.
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Introduction
Hypertension [OMIN #145500] is a common complex
disorder that is associated with both environmental and genetic
factors [1] and exhibits moderate to high estimates of heritability
ranging from 20% to 60% [2]. The disease has important public
health effects throughout the world. One of every four adults
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globally is hypertensive, and the number of adults with
hypertension in 2025 is predicted to increase by about 60% to a
total of 1.56 billion people [2]. In Taiwan, one-third of adult males
and one-fifth of adult females have hypertension [3]. Hypertension
is one of the most critical risk factors for cerebral hemorrhage and
infarction, coronary heart disease, heart failure, and kidney
disease. The combination of these diseases contributes to a
considerable proportion of mortality in the world.
Identifying hypertension susceptibility genes is potentially useful
for understanding the complex genetic mechanism. Screening high-
risk individuals and preventing disease development by early
lifestyle and pharmacological treatment can contribute to the
reduction of hypertension complications and cardiovascular
mortality. Efforts to identify hypertension susceptibility genes have
been ongoing for several decades. Candidate gene linkage analyses
and genome-wide linkage approaches have identified hypertension
susceptibility genes such as ECE (1p36.1) [4], AGT (1q42-43) [5,6],
AGTR1A (3q21-q25) [7], HYT1 (17q) [8,9], HYT2 (15q) [9], HYT3
(2p25-p24) [10], HYT4 (12p) [11], HYT5 (20q), HYT6 (5p) [12],
HYT7 (3p14.1-q12.3) [13], andHYT8 (18q21) [14]. In recent years,
many single nucleotide polymorphism (SNP) markers have been
discovered and broadly applied to study the genetics of complex
diseases [15]. Methods to map the genes of complex diseases have
evolved from linkage approaches for rare Mendelian traits to
genome-wide association studies (GWAS). Several GWAS have
been conducted for blood pressure or hypertension in recent
years [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34].
Blood pressure and hypertension susceptibility genes identified
using GWAS are summarized (Table 1). However, most studies
identified genes with small-to-moderate effects, and the genetic
variations identified so far collectively explain only a small fraction
of the genetic variability attributed to essential hypertension. In
addition, most studies were conducted with Caucasian samples.
Previous Asian studies were carried out primarily in Japanese and
Korean populations and the findings may or may not be applicable
to Han Chinese populations.
In 2009, we published the first young-onset hypertension (YOH)
genome-wide association mapping, which analyzed 175 patients
with hypertension and 175 normotensive matched controls with the
Affymetrix Human Mapping 100 K Set in the Han Chinese
population of Taiwan [29]. We selected YOH as the phenotype of
interest because it has a stronger genetic component than late-onset
hypertension. Because we aimed to identify more disease genes
responsible for YOH, we recruited more patient and control
samples (400 YOH patients and 400 normotensive matched
controls) and used a denser SNP genotyping platform (the Illumina
HumanHap550-Duo BeadChip which provides 546,376 autosomal
SNPs). There are 109 YOH patients and 98 normotensive controls
used in both YOH GWAS. In addition to a genome-wide SNP-
based association scan (genome-wide SBAS), based on an extension
of our previously developed gene-based algorithms [35], we
conducted a genome-wide gene-based association scan (genome-
wide GBAS) to increase power, diminish the effect of locus
heterogeneity, reduce the multiple testing burden, incorporate gene
information, and provide a direct interpretation of association
signals to genes. The genes identified with differential allelic
associations in patient and control groups were then validated with
gene expression analyses. We also studied expression quantitative
trait loci (eQTL) associated with the differentially expressed genes
identified in the present study and previous GWAS of hypertension
[16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34] and
linked them to hypertension. The analysis provides a deeper insight
of phenotype-genotype relationship and illustrates that whether
SNPs and genes influence YOH via gene regulation or via
mechanisms rather than varied gene expression. Moreover, two
replication analyses for this Taiwan Hypertension Study (TWNHS)
were performed using genotype data from the Hong Kong
Hypertension Study (HKHS) [36] and the Wellcome Trust Case-
Control Consortium Hypertension Study (WTCCCHS) [17]. The
HKHS collected samples from a Han Chinese population using a
family-based study design, and the WTCCCHS collected samples
from a Great Britain population using an independent case-control
study design. A flowchart for the overall study design and analysis
methods is provided in Figure 1 and elaborated in the Materials
and Methods section.
Results
Quality control and population stratification
For the 400 YOH patients and the 400 normotensive matched
controls genotyped with the Illumina HumanHap550-Duo
BeadChip, quality examination showed that all samples satisfied
the genotype call rate (GCR).0.99. One hypertensive patient and
the matched normotensive control were excluded from the
analysis due to an inconsistency of self-reported gender and X
chromosome. Following quality examination of the SNPs, 86
SNPs with a GCR,0.9 were removed, and 324 additional SNPs
were removed because of a departure from Hardy-Weinberg
equilibrium (HWE) (pFDR,1023) (where FDR is false discovery
rate). An additional 70,809 SNPs were removed because of a
minor allele frequency (MAF),0.01. Ultimately, 475,157 validat-
ed SNPs (,87% of autosomal SNPs on the HumanHap550-Duo
BeadChip) were analyzed in this study. The impact of population
substructures in our genome-wide SBAS and GBAS was
evaluated. The variance inflation fraction (VIF) was 1.027, which
is close to 1 and suggests that the population admixture with
respect to association tests was not significant in this study. The
principal component plot shows all hypertensive and normotensive
samples randomly mixed together (Figure S1). Moreover, the
results of non-parametric median tests also show no significant
differences between patient and control groups on the first ten
principal components (p-values for the first ten principal
components were 0.435, 0.523, 0.620, 0.178, 0.177, 0.435,
0.435, 0.831, 0.055 and 0.435). The results illustrate no
substructure in patient and control groups in this study.
Genome-wide SBAS
Initially, genome-wide SBAS was performed with four condi-
tional logistic regression models abbreviated ‘‘CLRN’’, ‘‘CLRC’’,
‘‘CLRN,BMI’’, and ‘‘CLRC,BMI’’, in which the subscript ‘‘N’’ stands
for a nominal SNP coding for a genotype-based analysis, and the
subscript ‘‘C’’ stands for a continuous SNP coding for a trend-
based analysis without or with a covariate adjustment for body
mass index (BMI). No significant SNPs (pFDR,1023 or p,1027)
were found. However, we observed that some genomic regions
contained a significant proportion of SNPs with marginal
significance (Figure S2A–S2D). For example, the region in
KIAA1797 between 20,638,805 bp and 20,993,372 bp on chro-
mosome 9p21 contains 84 SNPs probed on the Human-
Hap5502Duo BeadChip. The proportions of SNPs with marginal
significance (p,561022) in the four conditional logistic regression
analyses (CLRN, CLRC, CLRN,BMI, and CLRC,BMI) were 10%,
26%, 20%, and 23%, with the smallest values of p-values on
KIAA1797 of 7.5661024, 7.3861024, 4.3161025, and
7.6961026, respectively. P-values of genome-wide SBAS can be
downloaded at the website, http://pan.ibms.sinica.edu.tw/
hypertension/data.
Hypertension Susceptibility Genes in Han Chinese
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Genome-wide GBAS
Genome-wide GBAS was then applied to increase the statistical
power in the context of gene regions. The method of genome-wide
GBAS is introduced in Method S1. The analysis identified 101
potential hypertension susceptibility genes (pFDR,1023) in at
least one of the four genome-wide GBAS models, which combined
p-values obtained from the genome-wide SBAS (Figure 2A–2D;
Table S1). The 101 genes are classified into 12 categories
(Category I to XII) according to gene significance in the four
genome-wide GBAS models. In Table S1, three genes were
identified by all four genome-wide GBAS regression models
(Category I), six genes were identified by three of the four models
(Categories II, III and VII), 25 genes were identified by two of the
four models (Categories IV, V, VIII and X), and 67 genes were
identified by only one model (Categories VI, IX, XI and XII).
Empirical p-values of the 101 genes were calculated using a
permutation procedure with 10,000 replications. The gene-trait
association information collected from the Genetic Association
Database (GAD), Online Mendelian Inheritance in Man (OMIM),
and Mouse Genome Informatics (MGI) databases for the 101
genes is summarized in Table S2. All the genes (except for FMO5)
were successfully validated (pFDR,561022).
Gene expression analysis
As a validation process, gene expression analysis was conducted
to compare transcriptional levels of the 100 identified genes for 12
matched patient–control pairs in which the 12 matched pairs of
patients and controls were selected to have an extremely
discordant genotypic distribution between groups. The method
for selecting extremely discordant case-control pairs is introduced
inMethod S2. Among the 100 genes, gene expression data for 92
genes were provided by the Illumina HT12 Expression BeadChip,
of which 17 genes were differentially expressed (p,561022)
(Table 2). Beta coefficients and their standard errors from
ANCOVA are also provided (Table S3). Normalized gene
expression data of the 17 genes can be downloaded at the website,
http://pan.ibms.sinica.edu.tw/hypertension/data. These 17 genes
showed not only differential allelic distributions but also
differential transcriptional distributions between patient and
control groups. Based on the gene expression data of the 17
differentially expressed genes, a cluster analysis of 12 pairs of
hypertensive patients and normotensive controls only misclassified
one normotensive control to the patient group (Figure 3A). The
first three principal components of expression of the 17 genes
explained ,62% of the total variation for the 12 matched pairs of
Table 1. A summary table of blood pressure and hypertension susceptibility genes identified by using GWAS.
Ref Population Analysis (n= sample size) Blood pressure or hypertension- associated genes
[19] Multi-ethnicity Single-stage: GWAS (n = 1,260, 1,233 and 1,327
individuals in different analyses)
CCL20, WDR69, CDH13, LPP
[20] Asian ancestry – Japan Stage 1: GWAS (n = 188 cases+1,054 controls); Stage 2:
Replication (n = 752 cases+752 controls); Stage 3:
Replication (n = 619 cases+1,406 controls)
ADD2, KIAA0789, M6PR
[22] Amish Caucasian Stage 1: GWAS (n = 542 Amish Caucasians); Stage 2: Replication
(n = 1,367 Amish Caucasians and 5,804 non-Amish Caucasians)
STK39
[23] European ancestry Stage 1: GWAS (n = 34,433); Stage 2: Replication
(n = 71,225 subjects of European ancestry and 12,889
subjects of Indian Asian ancestry)
CYP17A1, CYP17A2, FGF5, SH2B3, MTHFR,
C10orf107a, ZNF652, PLCD3
[24] European ancestry – Germany Stage 1: GWAS (n = 1,017 Germany and 364 cases+596
controls); Stage 2: Replication (n = 1,551 Germany and 447
cases+1,119 controls); Stage 3: Replication (n = 1,097 Estonians
and 596 cases+650 controls; 2,401 British cases+1,969 controls)
CDH13
[25] Asian ancestry – Korea Stage 1: GWAS (n = 8,842 Koreans); Stage 2: Replication
(n = 7,861 Koreans)
ATP2B1
[26] African ancestry – America Stage 1: GWAS (n = 509 African American cases+508 controls);
Stage 2: Replication (n = 366 West African cases+614 controls)
SLC24A4, CACNA1H
[27] European ancestry Stage 1: GWAS (n = 29,136 European descent subjects);
Stage 2: Replication (n = 34,433 European descent subjects)
ATP2B1, CYP17A1, PLEKHA7, SH2B3, CACNB2,
CSK , ULK3, TBX3 , TBX5, ULK4
[28] Asian ancestry Stage 1: GWAS (n = 19,608 East Asian ancestry subjects);
Stage 2: Replication (n = 10,518 East Asian ancestry subjects)
ST7L , CAPZA1, FIGN , GRB14a, ENPEP, NPR3,
TBX3, ALDH2
[29] Asian ancestry – Taiwan Stage 1: GWAS (n = 175 cases+175 controls); Stage 2:
Replication (n = 833 cases+833 controls)
LOC344371, MYADML, FAM98A, RASGRP3, IMPG1
[30] African ancestry – America Stage 1: GWAS (n = 8,591 African Americans); Stage 2:
Replication (n = 11,882 African Americans); Stage 3:
Replication (n = 69,899 European Americans)
GPR98 , ARRDC3, C21orf91, SLC25A42, HLA-B
[31] European ancestry – Sweden Stage 1: GWAS (n = 1,621 cases+1,699 controls); Stage 2:
Replication (n = 19,845 cases+16,541 controls)
UMOD
[32] European ancestry –
Great Britain
Single-stage: GWAS (n = 2,000 cases+3,000 controls) GPR39, XRCC4, MYO6, ZFAT, MACROD2
[33] Asian ancestry – Korea Stage 1: GWAS (n = 7,551 Koreans); Stage 2: Replication
(n = 3,703 Koreans)
AKAP13
[34] Asian ancestry – Japan Stage 1: GWAS (n = 936 Japanese); Stage 2: Replication
(n = 3,228 Japanese); Stage 3: Replication (n = 2,895 Japanese)
CCBE1, MAP7, ZFP64, PCDH18, CDH2, WWOXa
aGenes (marked in bold) which were also identified to show differential allelic distributions between patient and control groups by our GBAS.
doi:10.1371/journal.pone.0032907.t001
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YOH patients and normotensive controls (Figure 3B). Fifteen of
the 17 genes had data of gene expression in mouse. Tissue-specific
analysis of gene expression showed that, except for LARS and
FURIN, other genes exhibited differential transcriptional distribu-
tions between genetically hypertensive and normotensive inbred
mouse strains in at least one tissue (p,561022) (Table 2). Beta
coefficients and their standard errors from ANOVA are also
provided (Table S3).
We made use of the Genevar database version 3.0.1 [37] to
investigate cis-acting expression quantitative trait loci (cis-eQTL)
associated with the 17 differentially expressed genes identified in our
human gene expression study (Table 2). Among the 17 genes, only
AP3S1 did not contain cis-eQTL. The gene-centric cis-eQTL analysis
found 361 cis-eQTL (p,561022) in 2-Mb windows around the 16
genes, where 285 cis-eQTL on 13 genes were interrogated in the
Illumina HumanHap550-Duo BeadChip. There were also 70 cis-
eQTL on 11 genes (TMEM56, KIAA1797, LARS, GRB14, IGF1,
WWOX,HLCS, CSF1, CSNK1G3,TTC12 and SYNE2) associated with
YOH in our TWNHS study (p,561022), where the disease
associated alleles of 40 cis-eQTL increased genetic risk of YOH as
well as up-regulated gene expression (Table S4). In addition to the
17 genes in Table 2, we also examined cis-eQTL of the
hypertension-associated genes identified by previous hypertension
genomic studies [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,
32,33,34] inTable 1 where GRB14 andWWOXwere excluded here
because they were also identified by the present study and their cis-
eQTL were already examined. Cis-eQTL of 54 genes were studied,
although 6 of these genes (CYP17A2,HLA-B, KIAA0789, LOC344371,
MYADML and ULK4) did not have cis-eQTL in Genevar database
[37]. The gene-centric cis-eQTL analysis found 1,902 cis-eQTL
(p,561022) in 2-Mb windows around the 48 genes, where 1,628 cis-
eQTL on 33 genes were interrogated in the Illumina Human-
Hap550-Duo BeadChip. Finally, 31 cis-eQTL on 9 genes (AKAP13,
CACNB2, CCBE1, CDH13, CSK, FIGN, LPP, SLC24A4 and TBX3)
were associated with YOH in our TWNHS study (p,561022),
where the disease associated alleles of 9 cis-eQTL increased genetic
risk of YOH as well as up-regulated gene expression (Table S5).
Replication analysis
In the HKHS replication analysis, genome-wide SBAS contained
‘‘sib-TDT’’, ‘‘QFAMSBP’’, ‘‘QFAMDBP’’, and ‘‘QFAMMBP’’ for
analyzing dichotomous disease status and three quantitative traits
Figure 1. An analysis flowchart of this study.
doi:10.1371/journal.pone.0032907.g001
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(quantitative systolic blood pressure [SBP], quantitative diastolic
blood pressure [DBP], and quantitative mean blood pressure
[MBP]). In the WTCCCHS, genome-wide SBAS was performed
with four logistic regression models abbreviated ‘‘LRN’’, ‘‘LRC’’,
‘‘LRN,Gender’’, and ‘‘LRC,Gender’’ in which the subscript ‘‘N’’ stands
for a nominal SNP coding for a genotype-based analysis, and the
subscript ‘‘C’’ stands for a continuous SNP coding for a trend-based
analysis with or without a covariate adjustment for gender. Among
the 17 genes that exhibited differential allelic distributions and
differential transcriptional distributions between patient and control
groups, four hypertension-associated genes (IGF1, SLC4A4,WWOX,
and SFMBT1) were further confirmed by replication studies. The
results are summarized in Table 3.
IGF1, which encodes insulin-like growth factor on 12q23.2, was
not only identified by the GBAS in our TWNHS [pCLRN=3.106
1027 (pFDRCLRN=2.47610
22); pCLRC=6.97610
211 (pFDRCLRC
=2.2061022); pCLRC,BMI=9.90610
28 (pFDRCLRC,BMI=2.956
1022)] and gene expression analysis [pANCOVA=3.21610
23] but
was also identified by a GBAS of the HKHS [pQFAMSBP=1.216
1024 (pFDRQFAMSBP=3.73610
22)]. Moreover, association between
gene expression and cis-eQTLmarkers of IGF1 was also found in our
gene-centric cis-eQTL analysis (Table S4). Two cis-eQTL of IGF1
were found (rs10860862 and rs5742632) where the latter SNP is an
intronic enhancer at a transcriptional factor binding site. IGF1 is a
well-documented gene that plays a role in cardiovascular disorders
[38,39,40,41,42] and metabolic disorders [43,44,45,46,47,48,49,
50,51,52]. IGF1 variants are associated with decreased body
weight/size, abnormal glucose homeostasis, increased/decreased
circulating insulin levels, decreased circulating IGF1 levels, and
increased DBP/SBP values in mice [53,54,55].
SLC4A4, which encodes the electrogenic sodium bicarbonate
cotransporter 1 on 4q21, was not only identified by our GBAS
[pCLRN,BMI=3.81610
25 (pFDRCLRN,BMI=2.99610
22); pCLRC,BMI
= 7.2661028 (pFDRCLRC,BMI=2.64610
22)] and gene expression
analysis [pANCOVA=3.14610
22] but was also identified by a GBAS
of the HKHS [pQFAMSBP=9.19610
26 (pFDRQFAMSBP=1.636
1022); pQFAMDBP=1.19610
23 (pFDRQFAMDBP=4.79610
22)]. This
gene is associated with decreased body weight/size, hematocrit, and
abnormal ion homeostasis in mice [56]. In addition, SLC4A5 is a
member of the same family of solute carriers as SLC4 and was also
shown to be associated with blood pressure [57] and with
hypertension [58].
Figure 2. Gene-based association tests based on p-values from the four conditional logistic regression models. (A) model CLRN, (B)
model CLRN,BMI, (C) model CLRC, and (D) model CLRC,BMI. In each figure, the vertical axis is the FDR-adjusted p-values (2log10 scale) of gene-based
association tests, and the horizontal axis is cumulative physical position (Mb scale). The red reference line signifies pFDR = 1023.
doi:10.1371/journal.pone.0032907.g002
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WWOX, which encodes the WW domain-containing protein on
16q23.3-q24.1, is the third gene that was simultaneously identified by
our genome-wide GBAS [pCLRC=7.47610
214 (pFDRCLRC=
5.7761023) and pCLRC,BMI=1.18610
28 (pFDRCLRC,BMI=1.846
1022)], gene expression analysis [pANCOVA=5.96610
23], and a
GBAS of the HKHS [psTDT=1.05610
26 (psTDT=1.37610
22) and
pQFAMMBP=8.82610
27 (pQFAMMBP=1.05610
22)]. Moreover, as-
sociation between gene expression and cis-eQTL markers ofWWOX
was also found in our gene-centric cis-eQTL analysis (Table S4). In
total, 24 cis-eQTL were found, where 14 cis-eQTL are intronic
enhancers at transcriptional factor binding sites, 1 cis-eQTL locates
in WWOX upstream, and the remaining 9 cis-eQTL are in an
intronic region with no known function. WWOX variants are
associated with hypoglycemia, hyperphosphatemia, decreased circu-
lating cholesterol levels and triglyceride levels, but with increased
blood uric acid levels in mice [59].WWOX variants were also found
to be associated with blood pressure in a previous Japanese GWAS
[23].
SFMBT1, which encodes the drosophila sex comb onmiddle (scm)-
like protein on 3p21.31 and contains four malignant brain tumor
repeat domains, was simultaneously identified by our genome-
wide GBAS [pCLRN=1.82610
210 (pFDRCLRN=2.47610
22) and
pCLRN,BMI=3.59610
29 (pFDRCLRN,BMI=2.81610
22)], gene ex-
pression analysis [pANCOVA=4.74610
22], and a GBAS of the
HKHS [pQFAMMBP=1.36610
25 (pFDRQFAMMBP=3.44610
22)].
This gene may have a novel role in hypertension, and its role in
disease etiology should be studied further.
Discussion
We conducted the first genome-wide GBAS, using a novel
region- and context-based method, to identify hypertension
susceptibility genes in a Han Chinese population. Four hyperten-
sion susceptibility genes, IGF1, SLC4A4, WWOX, and SFMBT1,
were found by a statistical permutation procedure, confirmed by
gene expression analysis, and further replicated using data from
the HKHS. Among them, IGF1, SLC4A4, and WWOX were
previously implicated as hypertension candidate genes in humans
and mice and are primarily associated with obesity, glucose
metabolism, and ion homeostasis, which are well-known mecha-
nisms of blood pressure regulation. SFMBT1 encoding a
drosophila scm-like protein is potentially involved in the
transcriptional repression of homeotic genes in embryonic
development via the histone methylation mechanism. Our study
shows that it may play a novel role in hypertension, but its disease
causing mechanism should be further elucidated [60]. Although
no genes identified by us were significantly confirmed by the
WTCCCHS data (Caucasian), COMMD7, which encodes COMM
domain-containing protein 7 on 20q11.21, was replicated with a
borderline significance (pFDRLRC= 7.46610
22). COMMD and
COMM domains 1–10 are extensively conserved in multicellular
eukaryotic organisms and define a novel family of structural and
functional homologs of MURR1/COMMD1 that suppress NF-
kappaB by affecting the association of NF-kappaB with chromatin
[61]. MURR1/COMMD1 is also a regulator of epithelial sodium
channels, and therefore may regulate blood pressure [62].
Some potential hypertension susceptibility genes were identified
by our genome-wide GBAS analysis and gene expression analysis
but were not replicated in the GBAS analysis of HKHS or
WTCCCHS. For example, TMEM56 on 1p21.3 and KIAA1797
on 9p21 were simultaneously identified by all four regression
models of our genome-wide GBAS. For these two genes, the
smallest p values in the genome-wide GBAS of the four regression
models were 6.78610220 and 1.03610236, respectively (Table 2),
and the largest proportion that SNPs satisfy p,1022 in a SBAS
among the four regression models is 58.82% and 27.38%,
Table 2. Seventeen genes with differential allelic and transcriptional distributions identified by the TWNHS.
Gene Raw p-values of GBAS of conditional logistic model
a,b Raw p-values of the human and mouse GE analysisa,b
CLRN CLRC CLRN,BMI CLRC,BMI Human Mouse aorta Mouse heart Mouse kidney Mouse liver
TMEM56 9.83E-14 6.78E-20 1.74E-12 1.19E-17 5.77E-03 3.81E-03 4.48E-02 5.31E-02 1.39E-02
KIAA1797 6.78E-16 1.13E-28 4.78E-29 1.03E-36 7.97E-03 NAc NAc NAc NAc
FMBT1 1.82E-10 6.93E-01 3.59E-09 6.93E-01 4.74E-02 7.53E-03 7.18E-01 1.00E-01 6.60E-01
LARS 2.80E-09 1.44E-05 5.28E-11 2.24E-05 6.83E-03 8.54E-01 7.77E-02 6.03E-01 1.38E-01
GRB14 2.56E-04 7.04E-12 8.64E-04 2.50E-08 7.15E-03 5.04E-01 3.79E-02 3.57E-02 2.21E-01
IGF1 3.10E-07 6.97E-11 3.10E-04 9.90E-08 3.21E-03 3.29E-02 5.70E-02 1.09E-01 1.71E-01
FURIN 3.62E-05 3.34E-08 4.76E-05 8.66E-08 2.26E-03 4.96E-01 1.72E-01 6.05E-01 6.51E-01
WWOX 1.70E-02 7.47E-14 2.23E-02 1.18E-08 5.96E-03 2.19E-02 9.94E-02 2.37E-01 4.22E-03
HLCS 5.88E-05 3.51E-08 5.15E-06 1.09E-12 1.38E-02 4.02E-02 1.28E-02 1.66E-01 1.90E-03
CSF1 5.66E-05 4.67E-08 8.36E-02 9.98E-06 2.76E-02 6.44E-03 7.60E-01 1.54E-02 3.20E-01
CSNK1G3 3.23E-02 3.39E-08 3.82E-01 1.06E-01 2.71E-03 1.10E-03 4.99E-03 2.85E-05 1.00E-01
COMMD7 2.50E-04 8.74E-09 1.18E-01 6.81E-04 2.62E-02 4.48E-02 6.55E-01 5.31E-01 7.99E-01
AP3S1 1.38E-02 5.17E-02 3.92E-08 3.22E-02 8.03E-03 NAc NAc NAc NAc
LC4A4 7.58E-01 1.90E-02 3.81E-05 7.26E-08 3.14E-02 3.32E-04 1.62E-03 4.42E-02 2.69E-01
LACE1 5.37E-01 4.82E-01 1.46E-03 4.24E-08 1.86E-02 4.14E-03 6.17E-01 2.96E-01 5.80E-01
TTC12 1.85E-03 1.01E-03 1.23E-02 2.03E-07 2.33E-02 4.69E-02 5.78E-07 2.87E-01 6.00E-01
SYNE2 9.62E-01 6.71E-01 2.63E-01 4.52E-08 1.61E-02 1.55E-01 4.71E-01 2.48E-02 2.18E-02
aTest results include p-values of the gene-based association analysis (CLRN, CLRC, CLRN,BMI, and CLRC,BMI) and 2log10(p) of gene expression [GE] analysis.
bRaw p-values of genes that reached pFDR,0.05 in GBAS of the TWNHS and p-values of genes that reached p,0.05 in gene expression studies are marked in bold.
cNA denotes that expression data of a gene were not available in the mouse gene expression analysis.
doi:10.1371/journal.pone.0032907.t002
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respectively. These two genes were validated by our human gene
expression analysis [TMEM56: pANCOVA=5.77610
23; KIAA1797:
pANCOVA=7.97610
23] andTMEM56was also validated by the mice
gene expression analysis [pANOVAaorta =3.81610
23; pANOVAheart
=4.4861022; pANOVAliver= 1.39610
22] (Table 2). In addition,
FURIN on 15q26.1, which encodes a subtilisin-like pro-protein con-
vertase family protein [GBAS: pCLRN=3.62610
25 (pFDRCLRN
=2.0461022); pCLRC=3.34610
28 (pFDRCLRC=1.52610
22);
pCLRN,BMI=4.76610
25 (pFDRCLRN,BMI=2.16610
22); pCLRC,BMI
=8.6661028 (pFDRCLRC,BMI=1.52610
22); gene expression:
pANCOVA=2.26610
23] (Table 2), has been associated with blood
pressure [63]. Due to the possibility of population specificity, these
genes should be further studied even though they were not replicated
in a GBAS of HKHS or WTCCCHS.
Our GBAS also identified some hypertension-associated genes
that showed differential allelic distributions between hypertensive
patients and normotensive controls and the genes could be
replicated by the GBAS of HKHS, even though no significant
differences in gene expression were observed. ACTN4 on 19q13 is
associated with cortical renal glomerulopathies, abnormal kidney
physiology, small kidney, proteinuria, and an abnormal blood urea
nitrogen level [64]. CYP7B1 on 8q21.3 is associated with
lipoproteins in humans [65] and is associated with abnormal
cholesterol homeostasis in mice [66]. FAS on 10q24.1 is associated
with hypertension [67], decreased body size, and increased body
weight in mice [68,69]. These SNPs may exert their effects via
mechanisms other than by varying gene expression.
This study investigated the association between DNA-level
variants (SNPs) and disease status of YOH by examining
differential allelic distributions between patient and control groups
and also investigated the association between mRNA-level variants
(gene expression) and disease status of YOH. An interesting
question to answer is whether SNP variants influence YOH
development via gene expression regulation. Therefore, we
examined whether the genes with differential allelic and expression
distributions between patient and control groups in the present
study were regulated by SNPs in the 2-Mb windows around the
differentially expressed genes (i.e., cis-eQTL mapping). Under a
less stringent criterion, 70 SNPs on 11 genes (TMEM56,
KIAA1797, LARS, GRB14, IGF1,WWOX, HLCS, CSF1, CSNK1G3,
TTC12 and SYNE2) were identified to be cis-eQTL, generating a
testable hypothesis that the 70 cis-eQTL may regulate hyperten-
sion-associated genes in turn to influence disease status.
Among the 11 genes, GRB14, which encodes a growth factor
receptor binding protein on 2q22-q24, can interact with insulin
receptors and insulin-like growth-factor receptors to modulate
insulin signaling in mice [70,71]. This gene was found to be
associated using GBAS and gene expression analyses of the
TWNHS, and had been identified in a previous GWAS of blood
pressure in East Asian populations [28]. Moreover, some
hypertension-associated cis-eQTL act as intronic enhancers at
transcriptional factor binding sites on this gene. This protein likely
has an inhibitory effect on receptor tyrosine kinase signaling and
thus on the insulin receptor signaling pathway, through which
Table 3. Replication analysis of the seventeen genes with differential allelic and transcriptional distributions in cases and controls.
Gene Raw p-values of GBAS of the HKHS
a,b Raw p-values of GBAS of the WTCCCHSa,b
sTDT QFAMSBP QFAMDBP QFAMMBP LRN LRC LRN,Gender LRC,Gender
TMEM56 5.60E-01 5.60E-01 5.60E-01 5.60E-01 8.06E-01 7.15E-01 7.69E-01 6.61E-01
KIAA1797 9.75E-01 9.86E-01 4.84E-01 9.86E-01 7.99E-01 9.34E-01 6.58E-01 9.34E-01
SFMBT1 3.04E-01 6.93E-01 2.91E-01 1.36E-05 5.12E-01 4.83E-01 5.12E-01 5.12E-01
LARS 2.26E-01 2.26E-01 2.26E-01 2.26E-01 3.37E-01 3.37E-01 3.37E-01 3.27E-01
GRB14 6.93E-01 6.93E-01 6.93E-01 6.93E-01 8.58E-01 8.58E-01 8.58E-01 8.58E-01
IGF1 2.02E-01 1.21E-04 6.03E-01 6.03E-01 8.06E-01 7.46E-01 7.84E-01 8.51E-01
FURIN 2.26E-01 2.26E-01 2.26E-01 2.26E-01 5.00E-02 5.00E-02 5.00E-02 5.00E-02
WWOX 1.05E-06 1.11E-03 1.54E-02 8.82E-07 3.83E-01 8.68E-01 3.85E-01 9.35E-01
HLCS 6.93E-01 5.08E-01 9.29E-01 9.34E-01 8.06E-01 4.36E-01 7.64E-01 6.16E-01
CSF1 4.31E-01 4.31E-01 4.26E-01 3.88E-01 5.66E-02 1.98E-02 6.00E-02 2.15E-02
CSNK1G3 5.82E-01 5.82E-01 5.82E-01 5.82E-01 1.44E-02 3.22E-01 1.19E-02 3.21E-01
COMMD7 2.26E-01 2.26E-01 2.26E-01 2.26E-01 6.71E-02 1.52E-03 3.06E-01 1.11E-02
AP3S1 3.37E-01 3.37E-01 3.37E-01 3.37E-01 2.26E-01 2.26E-01 2.26E-01 2.26E-01
SLC4A4 4.33E-02 9.19E-06 1.19E-03 4.61E-03 9.43E-01 6.76E-01 9.43E-01 6.87E-01
LACE1 4.58E-01 5.37E-01 5.37E-01 5.37E-01 7.38E-02 4.89E-02 7.23E-02 4.73E-02
TTC12 6.03E-01 7.20E-03 6.03E-01 2.01E-01 6.42E-01 6.42E-01 6.42E-01 6.42E-01
SYNE2 9.08E-01 8.78E-01 8.83E-01 9.61E-01 9.54E-01 8.76E-01 9.54E-01 8.85E-01
aTest results include p-values of GBAS of the HKHS (Method: sTDT, QFAMSBP, QFAMDBP, and QFAMMBP) and GBAS of the WTCCCHS (Method: LCN, LCC, LCN,Gender, and
LCC,Gender) of the 17 genes characterized by both differential allelic distributions and transcriptional distributions between patient and control groups.
bRaw p-values of genes that reached pFDR,561022 in the GBAS of the HKHS and the WTCCCHS are marked in bold.
doi:10.1371/journal.pone.0032907.t003
Figure 3. Evaluation of the 17 differentially expressed genes in hypertension. (A) Cluster analysis of transcriptional data from 12 pairs of
patients with hypertension (HT) and normotensive controls (NC). (B) Principal component analysis (PCA) of transcriptional data from 12 pairs of
patients with hypertension and normotensive controls), where the variation explained by the first two principal components (PC #1 and PC #2) is
39% and 13.1%.
doi:10.1371/journal.pone.0032907.g003
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GRB14 variants may exert their effect on the development of
hypertension. IGF1, another insulin-related gene which encodes
insulin-like growth factor on 12q23.2, was associated with
hypertension by GBAS and gene expression analyses of the
TWNHS, successfully validated by GBAS of the HKHS in this
study, and was previously associated with cardiovascular disorders
[38,39,40,41,42] and metabolic disorders [43,44,45,46,47,48,49
,50,51,52]. Some hypertension-associated cis-eQTL act as intronic
enhancers at transcriptional factor binding sites on this gene were
also found. WWOX was found relevant by GBAS and gene
expression analyses of the TWNHS, successfully validated by GBAS
of the HKHS in this study, identified by a previous GWAS in
hypertension in a Japanese population [34], and associated with
hypertension-related traits in mice [59]. Moreover, some hyperten-
sion-associated cis-eQTL which act as intronic enhancers at
transcriptional factor binding site on this gene were also found.
WWOX encoded protein is more than 90 percent identical to the
mouse protein responsible for modulation of tumor necrosis factor-
alpha-induced apoptosis and therefore suggests an apoptosis
correspondence for the human protein. This gene contains a
short-chain dehydrogenase/reductase domain and is highly ex-
pressed in hormonally regulated normal tissues such as ovary, testis,
and prostate. More recent evidence has suggested important roles of
WWOX in the suppression of tumor growth, the regulation of a wide
variety of cellular functions, steroid metabolism, and possibly
hypertension [72,73].
There were other cis-eQTL with relevant biological functions.
For example, five cis-eQTL on SYNE2 were found, where
rs9944035 is a missense variant leading to non-conservative
change, rs10140978 locates in promoter/regulatory region, and
rs1890908 is a missense variant leading conservative change.
Other examples include that rs10988 on LARS is a missense
variant leading to conservative change and rs333970 on LARS is a
splicing site. These cis-eQTL may play relevant roles in basic
genetics of gene regulation to confer susceptibility to YOH by
suppressing, inhibiting, enhancing or activating transcriptional
levels of the identified YOH associated genes.
In addition to examine cis-eQTL for our identified hyperten-
sion-associated genes in Table 2, we also used the Genevar
database [37] to investigate cis-eQTL for the hypertension-
associated genes in Table 1. Results showed that the genes
identified by our integrative analysis of SNP and gene expression
did contain a higher proportion of hypertension-associated cis-
eQTL than a SNP-only GWAS; the proportions of genes
containing hypertension-associated cis-eQTL were 0.846 versus
0.273 and the proportions of hypertension-associated cis-eQTL
SNPs in genes were 0.140 versus 0.019. This suggests the
importance of an integrative analysis of SNP and gene expression
in the post-GWAS era.
Our previous genome-wide association study of YOH analyzed
175 matched pairs of patients and normotensive controls
genotyped with the Affymetrix Human Mapping 100 K Set in
the Han Chinese population of Taiwan [29]. The study identified
a significant genetic interaction between rs1886985 on chromo-
some 6 and rs6129969 on chromosome 20. In addition, the study
also identified a significant SNP quartet composed of rs9308945,
rs6711736, rs6729869 and rs10495809 on chromosome 2, using a
sliding-window p-value combination method. We also attempted
to evaluate the genetic association of the six SNPs in the current
study of 400 matched pairs of YOH patients and normotensive
controls genotyped with the Illumina HumanHap550-Duo
BeadChip in the same Han Chinese population of Taiwan. SNPs
rs6711736 and rs10495809 are on the Illumina HumanHap550-
Duo BeadChip and SNPs rs1886985, rs6129969, rs9308945 and
rs6729869 were imputed based on the 1,000 Genomes Project
reference panel using IMPUTE2 [74]. Results show that genetic
association between YOH and the SNP quartet composed of
rs9308945, rs6711736, rs6729869 and rs10495809 on chromo-
some 2 was confirmed (pCLRN=1.79610
23, pCLRC= 1.31610
24,
and pCLRBMI = 2.96610
25), but genetic interaction between
rs1886985 and rs6129969 was not significant in this TWNHS.
The original WTCCCHS study only performed SBAS and no
significant SNPs or genes attained a genome-wide significance
level of 561027 [17]. In our WTCCCHS data analysis, we
performed both SBAS and GBAS to examine the 100 significant
genes identified by the genome-wide GBAS in our TWNHS. We
made a comparison of SBAS and GBAS in our WTCCCHS data
analysis based on the 87 genes (SNP data on 13 out of 100
significant genes were not available on the Affymetrix Human
Mapping 500 K Set). At a false discovery rate of pFDR,0.05,
GBAS identified three genes (ACTN4, CYP7B1 and PIP5K3) and
SBAS identified 2 genes (ACTN4 and TCF7L1). The concordance
rate of gene mapping results in SBAS and GBAS in our
WTCCCHS data analysis is 96.55%.
GBAS has some merits compared with SBAS [35,75,76].
Because GBAS combines genetic contributions of multiple SNPs
in a gene, the test power may be increased, and the effect of locus
heterogeneity on gene mapping may be alleviated. In addition, the
issue of over-correction with a large number of association tests in
a genome-wide association study is mitigated because the number
of association tests is reduced. Because the effect of the whole gene
is evaluated, the association results can be directly interpreted
using established gene functions and models. On the other hand,
the gene is a natural unit in which a set of SNPs can be combined.
Therefore, GBAS provides a convenient marker selection
alternative to LD-based or sliding-window strategies for a
genome-wide multilocus association scan. GBAS provides a
convenient, feasible, and powerful tool for identifying genes
involved in complex disorders.
Several limitations of this study should be noted when
interpreting the results. First, the phenotype definition and sample
ascertainment were not exactly the same in the three studies
(TWNHS, HKHS, and WTCCCHS). For example, the YOH
study in TWNHS recruited patients with hypertension with an age
of onset #50, but this criterion was not considered in HKHS or
WTCCCHS. Second, the three studies used different genome-
wide oligonucleotide SNP arrays. Therefore, the SNP markers that
were analyzed were different. Our study used the Illumina
HumanHap550-Duo BeadChip; HKHS used the Illumina
HumanHap610-quad BeadChip; WTCCCHS used the Affyme-
trix Human Mapping 500 K Set. Some association signals
identified by TWNHS could not be examined in the other two
studies due to a lack of SNPs in the regions of interest. Third, the
controls in the WTCCCHS data analysis were the 3,004 shared
community controls for seven complex diseases in WTCCC [17].
Some controls may not be normotensive and, therefore, the
association signal may be diluted due to a misclassification of
hypertensive patients to normotensive status. In other words,
significant association identified by TWNHS may be not
replicable in WTCCCHS due to the reduced power of
WTCCCHS. Finally, our current gene expression analysis aimed
to prioritize hypertension susceptibility genes for further confir-
mation. The sample size was somewhat small, although the
selected samples had extremely discordant genotype distributions.
The small sample size could lead to false negatives. Therefore, we
used a liberal multiple-testing correction in the expression data
analysis. In our next gene expression study, we will conduct a
large-scale gene expression study of 400 patients with hypertension
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and 400 normotensive controls using the Human OneArray
(Phalanx Biotech, Hsin-Chu, Taiwan), which provides ,300,000
genome probes to achieve more power.
Materials and Methods
Ethics statement
Written informed consent was obtained from each participant at
his/her initial clinic visit. The study was approved by the Internal
Review Board of Academia Sinica (Permit Number: AS-IRB01-
08012).
DNA samples
This TWNHS analyzed 400 matched pairs of patients with
hypertension and normotensive controls. Patients were recruited
from the Academia Sinica Multi-Center YOH Genetic Study. A
one-to-one match strategy for age (65 years) and gender was
applied to select 400 normal controls from the Taiwan Han
Chinese Cell and Genome Bank [77]. Immortalized cell lines from
their lymphocytes have been established. The criteria for sample
inclusion/exclusion and sample matching are described in our
previous GWAS [29]. Genetic association replication analysis was
performed using data from the other Han Chinese population in
Hong Kong (HKHS) [36] and a Caucasian population
(WTCCCHS) [17]. The HKHS collected 111 families with a
total of 315 individuals, including 37 affected sib pairs and 195
discordant sib pairs. SBP, DBP, MBP off treatment, and disease
status of hypertension were measured. The WTCCCHS collected
1,999 patients with hypertension and 3,004 normal controls
consisting of 1,504 samples from the 1958 British Birth Cohort
and 1,500 samples from the UK Blood Service Control Group
[17].
SNP genotyping experiments
The genomic DNA of 800 Han Chinese samples was isolated
from leukocytes using a Puregene kit (Gentra Systems, Minneap-
olis, MN, USA) for genomic DNA isolation. The DNA
concentration was quantified and adjusted to 60 ng/ml using a
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technolo-
gies, DE, USA). All samples were genotyped by deCODE
Genetics (Reykjavik, Iceland) with the Illumina HumanHap550-
Duo BeadChip (Illumina, Inc., San Diego, CA, USA). This SNP
genotyping platform contains 560,186 tagging SNPs selected from
phases I and II of the HapMap Project [78,79,80,81]. Genotype
calling was performed using the Illumina BeadStudio Genotyping
Module (Illumina, Inc.). Samples in the HKHS were genotyped
with the Illumina HumanHap610-quad BeadChip (Illumina, Inc.),
which enables the whole-genome genotyping of 620,901 SNPs.
Samples in the WTCCCHS were genotyped with the Affymetrix
Human Mapping 500 K Set (Affymetrix, Inc., San Diego, CA,
USA), which provides 500,568 SNPs. The genotyping experiment
was described previously [17].
Gene expression microarray experiments
A total of 12 matched pairs of patients with hypertension with
the highest risk scores and normotensive controls with the lowest
risk scores were selected. Total RNA was extracted using TRIzol
Reagent (Life Technologies, Inc., CA, USA) and then reverse
transcribed to cDNA and cRNA using Illumina TotalPrepTM
RNA Amplification Kit (Illumina, Inc.). The cRNA concentration
was quantified and adjusted to 150 ng/ml using a NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies, DE, USA).
Gene expression experiments were performed by Genetech
Biotech (Taipei, Taiwan) with the Illumina HT12 Expression
BeadChip (Illumina, Inc.). This gene expression platform contains
more than 25,000 annotated genes and more than 48,000 probes
derived from the NCBI RefSeq (Build 36.2, Rel 22) and the
UniGene (Build 199) databases. We also analyzed the gene
expression data sets of genetically hypertensive and normotensive
inbred mouse strains. Tissues of aorta, heart, kidney and liver from
the two mouse strains were collected. The details about tissue
collection, RNA preparation, and microarray experiment was
described previously [82].
Statistical analyses
A flowchart for the overall study design is provided (Figure 1).
Quality of samples and SNPs were examined and population
stratification in the TWNHS was evaluated. Genome-wide SBAS
and GBAS were performed and confirmed by microarray gene
expression analyses for the Han Chinese population of Taiwan.
The identified genes were further examined by two association
studies, the HKHS and the WTCCCHS. The detailed analysis
procedures are as follows.
First, sample and SNP quality were examined. We checked the
consistency of self-reported gender and X chromosome, calculated
the GCR, estimated MAF using an allele counting approach, and
examined HWE using an exact HWE test [83] with SAS
GENETICS (SAS Institute, Inc., Cary, NC, USA) for all
546,376 autosomal SNPs from 560,184 tag SNPs probed on the
HumanHap550-Duo BeadChip. Second, population stratification
and admixture were examined. We evaluated population structure
using a genomic control method [84] with SAS GENETICS (SAS
Institute, Inc.) and a principal component method with EigenStrat
software [85]. A non-parametric median test was used to examine
differences of principal components in case and control groups
[86].
Third, genome-wide SBAS was performed based on conditional
logistic regression analyses using SAS STAT (SAS Institute, Inc.).
The analysis regressed a dichotomous response on a nominal SNP
coding for a genotype-based analysis or a continuous SNP coding
for a trend-based analysis at each SNP locus with or without a
covariate adjustment for BMI, resulting in four models: (1)
conditional logistic regression with a nominal genotype without
BMI adjustment (‘‘CLRN’’), (2) conditional logistic regression with
a continuous genotype without BMI adjustment (‘‘CLRC’’), (3)
conditional logistic regression with a nominal genotype and BMI
adjustment (‘‘CLRN,BMI’’), and (4) conditional logistic regression
with a continuous genotype and BMI adjustment (‘‘CLRC,BMI’’).
For each SNP locus, p-values of a one degree-of-freedomWald test
were calculated for model CLRC and CLRC,BMI, and p-values of a
two degree-of-freedom Wald test were calculated for model CLRN
and CLRN,BMI.
Fourth, genome-wide GBAS was performed. According to
SNP- and gene-annotation provided by the SNPper database [87],
all 475,157 validated SNPs were divided into 216,994 intragenic
SNPs on 15,373 genes and 258,163 intergenic SNPs. If a SNP
mapped to more than one gene, it was assigned randomly. The
mean, median, and standard deviation of the number of SNPs
within a gene were 14.12, 6.00, and 32.19, respectively. In
summary, 1,688 genes (10.98%), 9,000 genes (58.57%), 4,387
genes (28.55%), 291 genes (1.89%), and 1 gene (,0.01%)
contained 1, 2–10, 11–100, 101–1000, and .1000 SNPs; CSMD1
on chromosome 8 contained the most SNPs (1,518) of any gene.
In the first step (prioritization test) of GBAS, we prioritized
genes using a more stringent criterion (pFDR,1023) to reduce the
potential inflated significance. For each of the 15,373 genes, with a
specific regression model, p-values of intragenic SNPs within the
same gene were combined by calculating a truncated product p-
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value test statistic [88,89,90] with a p-value truncation threshold of
0.05 to represent a gene [35]. An FDR [91] was calculated using
SAS GENETICS (SAS Institute, Inc.) to account for a multiple
test correction. Genome-wide statistical significance of gene-based
association tests was evaluated by adjusting for multiple tests of all
genes using a stringent threshold, pFDR,1023. The identified
candidate genes were further validated in the next step by using a
permutation test for a stringent consideration. In the second step
(permutation test) of GBAS, we used the threshold conventionally
adopted (pFDR,561022) to further remove the inflated signif-
icance in the first test and take p-value dependency into
consideration. Then, 10,000 permutations that we permuted for
disease status but that maintained the matched relationship
between patients and controls were performed for calculation of
empirical p-values. In each permutation sample, we determined
the statistical significance of the identified genes using the same
gene-based association test. Empirical p-values of each identified
gene were calculated and adjusted by FDR, where FDR was
calculated across four models (‘‘CLRN’’, ‘‘CLRC’’, ‘‘CLRN,BMI’’
and ‘‘CLRC,BMI’’) jointly. For association validation of the
identified genes, statistical significance was claimed under a
significance threshold of pFDR,561022. The details of our
genome-wide GBAS method are described in Method S1.
Fifth, microarray gene expression analysis was performed.
Based on the genes identified in the second step, we selected 12
patients and 12 controls with extremely discordant genotypic
distributions between the patient and control groups and
conducted a microarray gene expression study using the Illumina
HT-12 Expression Beadchip (Illumina, Inc.). Genotypes of all
SNPs in the genes identified in the second step were assigned as
‘‘risky genotypes’’ or ‘‘protective genotypes’’ if the genotype
frequencies in case group were higher or lower than in control
group, respectively. The average proportion of risky genotypes in
every patient and average proportion of protective genotypes in
every control were calculated for every control over the identified
genes. The 12 patients who carried the maximum proportion of
risky genotypes and the 12 controls who carried the maximum
proportion of protective genotypes among all samples were
selected. The details of the selection of extremely discordant
case-control pairs are described in Method S2. Quantile
normalization [92] was applied to normalize gene expression,
and analysis of covariance (ANCOVA) with an adjustment for
BMI using PARTEK software (Partek, Inc., St. Louis, Missouri,
USA) was performed to analyze the normalized data and identify
the differentially expressed genes among the 100 identified genes.
Confirmation of genetic association was claimed if pAN-
COVA,5610
22. The identified differentially expressed genes were
used to perform a cluster analysis with an average linkage in which
distances of any two samples were measured by Kendall’s
dissimilarity [93]. Except for two genes, KIAA1797 and AP3S1,
not available in the mouse gene expression study [82], analysis of
variance (ANOVA) using SAS STAT (SAS Institute, Inc.) was
performed to discuss tissue-specific variation in gene expression
between genetically hypertensive and normotensive mouse strains.
Confirmation of genetic association was claimed if pA-
NOVA,5610
22.
Sixth, we performed gene-centric cis-acting expression quanti-
tative trait loci (cis-eQTL) analysis by using the lymphoblastoid
cell line datasets in Geneva GenCord [94] and MuTHER [95]
provided in the Genevar (GENe Expression VARiation) [37]. The
analysis examined the association between gene expressions and
SNPs in 2-Mb windows around the differentially expressed genes
identified in our gene expression study (Table 2) and hyperten-
sion-associated genes identified in previous hypertension genomic
studies (Table 1); Spearman’s correlation coefficient and
correlation test of gene expressions and continuous SNP coding
were calculated. Cis-eQTL with p,561022 were selected.
Furthermore, we examined if the cis-eQTL were also associated
with YOH in the TWNHS; conditional logistic regression at each
cis-eQTL was performed with or without a covariate adjustment
for BMI by using SAS STAT (SAS Institute, Inc.), where a
continuous SNP coding was considered. YOH-associated Cis-
eQTL with p,561022 were selected. Finally, we examined the
direction of genetic effect (risky effect or protective effect) and gene
regulation (up-regulation or down-regulation) of the disease
associated alleles of cis-eQTL.
Finally, we conducted GBAS for genomic data sets of a Han
Chinese population of Hong Kong and a Caucasian population.
We analyzed genotype data of SNPs on the 100 identified genes
and four phenotypes from the HKHS GWAS. The four
phenotypes were: (1) dichotomous disease status, (2) quantitative
SBP, (3) quantitative DBP, and (4) quantitative MBP. A single-
locus sib-based transmission disequilibrium test (sib-TDT) [96]
was applied to examine the genetic association of the dichotomous
disease status of hypertension with the SNPs. A quantitative
family-based association test (QFAM) [97] was applied to examine
the genetic association of quantitative SBP, DBP, MBP, and genes
(‘‘QFAMSBP’’, ‘‘QFAMDBP’’, and ‘‘QFAMMBP’’) by calculating p-
values for a within-family component. All the analyses were done
with PLINK software [97]. Moreover, we permuted the disease
status to obtain 10,000 permutation samples for calculation of
empirical p-values. In each permutation sample, we examined the
statistical significance of the identified genes using the same gene-
based association test described in the fourth step. The empirical
p-value of each identified gene was calculated and adjusted by
FDR, where FDR was calculated across four phenotypic models
(‘‘sib-TDT’’, ‘‘QFAMSBP’’, ‘‘QFAMDBP’’, and ‘‘QFAMMBP’’)
jointly.
Replication of genetic association was claimed if
pFDR,561022. We also analyzed genotype data from the
WTCCCHS [17]. Single-locus association tests were performed
using logistic regression analyses, which regressed a dichotomous
response on continuous or nominal-coding genotypes at each SNP
locus with or without covariate adjustment for gender, resulting in
four logistic regression models: (1) logistic regression with a
nominal genotype without gender adjustment (‘‘LRN’’), (2) logistic
regression with a continuous genotype without gender adjustment
(‘‘LRC’’), (3) logistic regression with a nominal genotype with
gender adjustment (‘‘LRN,Gender’’), and (4) logistic regression with
a continuous genotype with gender adjustment (‘‘LRC,Gender’’).
Again, we permuted the disease status to obtain 10,000
permutation samples for calculation of empirical p-values. In each
permutation sample, we determined the statistical significance of
the identified genes using the same gene-based association test
described in the fourth step. The empirical p-value of each
identified gene was calculated and adjusted by FDR, where FDR
was calculated across four models (‘‘LRN’’, ‘‘LRC’’, ‘‘LRN,Gender’’,
and ‘‘LRC,Gender’’) jointly. Replication of genetic association was
claimed if pFDR,561022. Note that 13 genes out of 100 were
not examined in the WTCCCHS because the Affymetrix Human
Mapping 500 K Set does not provide SNPs on these 13 genes.
Bioinformatics analyses
We used the Genetic Association Database (GAD, http://
geneticassociationdb.nih.gov/cgi-bin/index.cgi) and Online Men-
delian Inheritance in Man (OMIM, http://www.ncbi.nlm.nih.
gov/omim/) to determine whether the identified genes with
differential allelic associations and differential expression in
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patients with hypertension and normotensive controls were also
reported. In addition, we used Mouse Genome Informatics (MGI,
http://www.informatics.jax.org/) to determine if the identified
genes were involved in hypertension-related phenotypes in mice
and other mammals.
Supporting Information
Figure S1 Principal component analysis for evaluation
of the population substructure in patient and control
groups. Hypertensive patients (symbol: #) and normotensive
controls (symbol:6) are projected onto a two-dimensional plane
defined by the first two eigenvectors.
(DOC)
Figure S2 P-values (2log10 scale) of genome-wide SBAS.
(A) P-values of the conditional logistic regression with a nominal
genotype without BMI adjustment (CLRN). (B) P-values of the
conditional logistic regression with a nominal genotype with BMI
adjustment (CLRN,BMI). (C) P-values of the conditional logistic
regression with a continuous genotype without BMI adjustment
(CLRC). (D) P-values of the conditional logistic regression with a
continuous genotype with BMI adjustment (CLRC,BMI). In each
figure, the vertical axis is the raw p-values (2log10 scale) of gene-
based association tests, and the horizontal axis is cumulative
physical position (Mb scale).
(DOC)
Table S1 Raw p-values (2log10 scale) of 101 genes
identified by the genome-wide GBAS. Gene name, number
of SNPs, chromosome, physical position, and category (the 101
genes are classified into 12 categories (Category I to XII) according
to gene significance in the four genome-wide GBAS models) are
shown. The raw p-values in2log10 scale are shown for our GBAS
of the TWNHS (Method: CLRN, CLRC, CLRN,BMI, and
CLRC,BMI) and gene expression analysis (Method: ANCOVA) in
order. Raw p-values that reached pFDR,561022 in each model
are marked in bold.
(XLS)
Table S2 The information for the 101 identified hyper-
tension susceptibility genes collected from the GAD,
OMIM, and MGI databases.
(XLS)
Table S3 Beta coefficients and their standard errors for
the 17 differentially expressed genes in hypertension.
(DOC)
Table S4 The cis-eQTL analysis of 17 genes in Table 2
identified in the present study. Gene name followed by
chromosome number, RS number of cis-eQTL, beta coefficient in
CLRC, beta coefficient in CLRC,BMI, p-values of the tests of beta
coefficients, the maximal Spearman correlation coefficient from
Geneva GenCord and MuTHER, p-value of the test of Spearman
correlation, and the first and the second allele followed by an index
for the direction of genetic effect and gene regulation of the YOH-
associated risky alleles in the cis-eQTL (r/u, r/d, p/u and p/d
denote that risky/up-regulated, risky/down-regulated, protective/
up-regulated and protective/down-regulated, respectively). ‘‘NS’’
indicates that beta coefficient is not significant and p-value is not
shown. ‘‘NC’’ indicates that the positive/negative of Spearman
correlation coefficients from Geneva GenCord and MuTHER is
not consistent.
(XLS)
Table S5 The cis-eQTL analysis of 54 genes in Table 1
identified by previous GWAS in hypertension. Gene name
followed by chromosome number, RS number of cis-eQTL, beta
coefficient in CLRC, beta coefficient in CLRC,BMI, p-values of the
tests of beta coefficients, the maximal Spearman correlation
coefficient from Geneva GenCord and MuTHER, p-value of the
test of Spearman correlation, and the first and the second allele
followed by an index for the direction of genetic effect and gene
regulation of the YOH-associated risky alleles in the cis-eQTL (r/
u, r/d, p/u and p/d denote that risky/up-regulated, risky/down-
regulated, protective/up-regulated and protective/down-regulat-
ed, respectively). ‘‘NS’’ indicates that beta coefficient is not
significant and p-value is not shown. ‘‘NC’’ indicates that the
positive/negative of Spearman correlation coefficients from
Geneva GenCord and MuTHER is not consistent.
(XLS)
Method S1 Genome-wide gene-based association tests.
(DOC)
Method S2 Selection of extremely discordant case-
control pairs.
(DOC)
Acknowledgments
This study made use of data obtained from the Wellcome Trust Case
Control Consortium. A full list of the investigators who contributed to the
generation of the data is available from www.wtccc.org.uk. We sincerely
thank two anonymous reviewers for their very constructive and insightful
comments that helped in preparing our revision.
Author Contributions
Conceived and designed the experiments: HCY WHP. Performed the
experiments: JWC HYH CTT T. Lin SHS WCT JHC HBL WHY TYC
CIC SJL. Analyzed the data: HCY YJL KMC CMC YG. Contributed
reagents/materials/analysis tools: HCY JWC HYH CTT T. Lin SHS
WCT JHC HBL WHY TYC CIC SJL GNT BT PCS SSC T. Lam WHP.
Wrote the paper: HCY WHP.
References
1. Pickering G (1978) Normotension and hypertension: the mysterious viability of
the false. The American Journal of Medicine 65: 561–563.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, et al. (2005)
Global burden of hypertension: analysis of worldwide data. Lancet 365: 217–223.
3. Pan WH, Chang HY, Yeh WT, Hsiao SY, Hung YT (2001) Prevalence,
awareness, treatment and control of hypertension in Taiwan: results of Nutrition
and Health Survey in Taiwan (NAHSIT) 1993–1996. Journal of Human
Hypertension 15: 793–798.
4. Funke-Kaiser H, Reichenberger F, Kopke K, Herrmann SM, Pfeifer J, et al.
(2003) Differential binding of transcription factor E2F-2 to the endothelin-
converting enzyme-1b promoter affects blood pressure regulation. Human
Molecular Genetics 12: 423–433.
5. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, et al.
(1992) Molecular basis of human hypertension: role of angiotensinogen. Cell 71:
169–180.
6. Lifton RP (1996) Molecular genetics of human blood pressure variation. Science
272: 676–680.
7. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, et al. (1994)
Angiotensin II type 1 receptor gene polymorphisms in human essential
hypertension. Hypertension 24: 63–69.
8. Julier C, Delepine M, Keavney B, Terwilliger J, Davis S, et al. (1997) Genetic
susceptibility for human familial essential hypertension in a region of homology
with blood pressure linkage on rat chromosome 10. Human Molecular Genetics
6: 2077–2085.
9. Xu X, Rogus JJ, Terwedow HA, Yang J, Wang Z, et al. (1999) An extreme-sib-
pair genome scan for genes regulating blood pressure. American Journal of
Human Genetics 64: 1694–1701.
10. Angius A, Petretto E, Maestrale GB, Forabosco P, Casu G, et al. (2002) A new
essential hypertension susceptibility locus on chromosome 2p24-p25, detected by
genomewide search. American Journal of Human Genetics 71: 893–905.
Hypertension Susceptibility Genes in Han Chinese
PLoS ONE | www.plosone.org 12 March 2012 | Volume 7 | Issue 3 | e32907
11. Gong M, Zhang H, Schulz H, Lee YA, Sun K, et al. (2003) Genome-wide
linkage reveals a locus for human essential (primary) hypertension on
chromosome 12p. Human Molecular Genetics 12: 1273–1277.
12. Wallace C, Xue MZ, Newhouse SJ, Marcano AC, Onipinla AK, et al. (2006)
Linkage analysis using co-phenotypes in the BRIGHT study reveals novel
potential susceptibility loci for hypertension. American Journal of Human
Genetics 79: 323–331.
13. Koivukoski L, Fisher SA, Kanninen T, Lewis CM, von Wowern F, et al. (2004)
Meta-analysis of genome-wide scans for hypertension and blood pressure in
Caucasians shows evidence of susceptibility regions on chromosomes 2 and 3.
Human Molecular Genetics 13: 2325–2332.
14. Guzman B, Cormand B, Ribases M, Gonzalez-Nunez D, Botey A, et al. (2006)
Implication of chromosome 18 in hypertension by sibling pair and association
analyses: putative involvement of the RKHD2 gene. Hypertension 48: 883–891.
15. Cowley AW (2006) The genetic dissection of essential hypertension. Nature
Reviews Genetics 7: 829–840.
16. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, et al. (2009)
Genome-wide association analysis of metabolic traits in a birth cohort from a
founder population. Nature Genetics 41: 35–46.
17. The Wellcome Trust Case Control Consortium (2007) Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447: 661–678.
18. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PIW, et al. (2007)
Genome-wide association analysis identifies loci for type 2 diabetes and
triglyceride levels. Science 316: 1331–1336.
19. Levy D, Larson MG, Benjamin EJ, Newton-Cheh C, Wang TJ, et al. (2007)
Framingham Heart Study 100 K Project: genome-wide associations for blood
pressure and arterial stiffness. BMC Medical Genetics 8 Suppl 1: S3.
20. Kato N, Miyata T, Tabara Y, Katsuya T, Yanai K, et al. (2008) High-density
association study and nomination of susceptibility genes for hypertension in the
Japanese National Project. Human Molecular Genetics 17: 617–627.
21. Psaty BM, O’Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, et al. (2009)
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Consortium: Design of prospective meta-analyses of genome-wide association
studies from 5 cohorts. Circulation: Cardiovascular Genetics 2: 73–80.
22. Wang Y, O’Connell JR, McArdle PF, Wade JB, Dorff SE, et al. (2009) Whole-
genome association study identifies STK39 as a hypertension susceptibility gene.
Proceedings of the National Academy of Sciences of the United States of
America 106: 226–231.
23. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, et al. (2009)
Genome-wide association study identifies eight loci associated with blood
pressure. Nature Genetics 41: 666–676.
24. Org E, Eyheramendy S, Juhanson P, Gieger C, Lichtner P, et al. (2009)
Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing
to blood pressure determination in two European populations. Human
Molecular Genetics 18: 2288–2296.
25. Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, et al. (2009) A large-scale genome-
wide association study of Asian populations uncovers genetic factors influencing
eight quantitative traits. Nature Genetics 41: 527–534.
26. Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, et al. (2009) A
genome-wide association study of hypertension and blood pressure in African
Americans. PLoS Genetics 5: e1000564.
27. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, et al. (2009) Genome-
wide association study of blood pressure and hypertension. Nature Genetics 41:
677–687.
28. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, et al. (2011) Meta-analysis of
genome-wide association studies identifies common variants associated with
blood pressure variation in east Asians. Nature Genetics 43: 531–538.
29. Yang H-C, Liang Y-J, Wu Y-L, Chung C-M, Chiang K-M, et al. (2009)
Genome-wide association study of young-onset hypertension in the Han Chinese
population of Taiwan. PLoS One 4: e5459.
30. Fox ER, Young JH, Li Y, Dreisbach AW, Keating BJ, et al. (2011) Association of
genetic variation with systolic and diastolic blood pressure among African
Americans: the Candidate Gene Association Resource study. Human Molecular
Genetics 20: 2273–2284.
31. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, et al. (2010)
Genome-wide association study of blood pressure extremes identifies variant
near UMOD associated with hypertension. PLoS Genetics 6: e1001177.
32. Slavin TP, Feng T, Schnell A, Zhu X, Elston RC (2011) Two-marker association
tests yield new disease associations for coronary artery disease and hypertension.
Human Genetics.
33. Hong K-W, Lim J-E, Oh B (2011) A regulatory SNP in AKAP13 is associated
with blood pressure in Koreans. Journal of Human Genetics 56: 205–210.
34. Hiura Y, Tabara Y, Kokubo Y, Okamura T, Miki T, et al. (2010) A genome-
wide association study of hypertension-related phenotypes in a Japanese
population. Circulation Journal 74: 2353–2359.
35. Yang H-C, Liang Y-J, Chung C-M, Chen J-W, Pan W-H (2009) Genome-wide
gene-based association study. BMC Proceedings 3: S135.
36. Fang Y-J, Deng H-B, Thomas GN, Tzang CH, Li C-X, et al. (2010) Linkage of
angiotensinogen gene polymorphisms with hypertension in a sibling study of
Hong Kong Chinese. Journal of Hypertension 28: 1203–1209.
37. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, et al.
(2010) Genevar: a database and Java application for the analysis and
visualization of SNP-gene associations in eQTL studies. Bioinformatics 26:
2474–2476.
38. Schut AF, Janssen JA, Deinum J, Vergeer JM, Hofman A, et al. (2003)
Polymorphism in the promoter region of the insulin-like growth factor I gene is
related to carotid intima-media thickness and aortic pulse wave velocity in
subjects with hypertension. Stroke 34: 1623–1627.
39. Yazdanpanah M, Rietveld I, Janssen JA, Njajou OT, Hofman A, et al. (2006)
An insulin-like growth factor-I promoter polymorphism is associated with
increased mortality in subjects with myocardial infarction in an elderly
Caucasian population. The American Journal of Cardiology 97: 1274–1276.
40. Ruigrok YM, Slooter AJ, Bardoel A, Frijns CJ, Rinkel GJ, et al. (2005) Genes
and outcome after aneurysmal subarachnoid haemorrhage. Journal of
Neurology 252: 417–422.
41. Telgmann R, Dordelmann C, Brand E, Nicaud V, Hagedorn C, et al. (2009)
Molecular genetic analysis of a human insulin-like growth factor 1 promoter P1
variation. FASEB Journal 23: 1303–1313.
42. Horio T, Kamide K, Takiuchi S, Yoshii M, Miwa Y, et al. (2010) Association of
insulin-like growth factor-1 receptor gene polymorphisms with left ventricular
mass and geometry in essential hypertension. Journal of Human Hypertension
24: 320–326.
43. te Velde SJ, van Rossum EF, Voorhoeve PG, Twisk JW, Delemarre van de
Waal HA, et al. (2005) An IGF-I promoter polymorphism modifies the
relationships between birth weight and risk factors for cardiovascular disease and
diabetes at age 36. BMC Endocrine Disorders 5: 5.
44. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, et al. (2004)
Association of the polycystic ovary syndrome with genomic variants related to
insulin resistance, type 2 diabetes mellitus, and obesity. Journal of Clinical
Endocrinology & Metabolism 89: 2640–2646.
45. ’t Hart LM, Fritsche A, Rietveld I, Dekker JM, Nijpels G, et al. (2004) Genetic
factors and insulin secretion: gene variants in the IGF genes. Diabetes 53 Suppl
1: S26–30.
46. Voorhoeve PG, van Rossum EF, Te Velde SJ, Koper JW, Kemper HC, et al.
(2006) Association between an IGF-I gene polymorphism and body fatness:
differences between generations. European Journal of Endocrinology 154:
379–388.
47. Sweeney C, Murtaugh MA, Baumgartner KB, Byers T, Giuliano AR, et al.
(2005) Insulin-like growth factor pathway polymorphisms associated with body
size in Hispanic and non-Hispanic white women. Cancer Epidemiology,
Biomarkers & Prevention 14: 1802–1809.
48. Rietveld I, Janssen JA, van Rossum EF, Houwing-Duistermaat JJ, Rivadeneira F,
et al. (2004) A polymorphic CA repeat in the IGF-I gene is associated with
gender-specific differences in body height, but has no effect on the secular trend
in body height. Clinical Endocrinology 61: 195–203.
49. Rietveld I, Hofman A, Pols HA, van Duijn CM, Lamberts SW, et al. (2006) An
insulin-like growth factor-I gene polymorphism modifies the risk of microalbu-
minuria in subjects with an abnormal glucose tolerance. European Journal of
Endocrinology 154: 715–721.
50. Landmann E, Geller F, Schilling J, Rudloff S, Foeller-Gaudier E, et al. (2006)
Absence of the wild-type allele (192 base pairs) of a polymorphism in the
promoter region of the IGF-I gene but not a polymorphism in the insulin gene
variable number of tandem repeat locus is associated with accelerated weight
gain in infancy. Pediatrics 118: 2374–2379.
51. Knight J, Sham P (2006) Design and analysis of association studies using pooled
DNA from large twin samples. Behavior Genetics 36: 665–677.
52. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New
genetic loci implicated in fasting glucose homeostasis and their impact on type 2
diabetes risk. Nature Genetics 42: 105–116.
53. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A (1993) Mice carrying
null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type
1 IGF receptor (Igf1r). Cell 75: 59–72.
54. Ueki I, Ooi GT, Tremblay ML, Hurst KR, Bach LA, et al. (2000) Inactivation
of the acid labile subunit gene in mice results in mild retardation of postnatal
growth despite profound disruptions in the circulating insulin-like growth factor
system. Proceedings of the National Academy of Sciences of the United States of
America 97: 6868–6873.
55. Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A (2008) The
hormonal action of IGF1 in postnatal mouse growth. Proceedings of the
National Academy of Sciences of the United States of America 105:
19378–19383.
56. Gawenis LR, Bradford EM, Prasad V, Lorenz JN, Simpson JE, et al. (2007)
Colonic anion secretory defects and metabolic acidosis in mice lacking the
NBC1 Na+/HCO3- cotransporter. Journal of Biological Chemistry 282:
9042–9052.
57. Hunt SC, Xin Y, Wu LL, Cawthon RM, Coon H, et al. (2006) Sodium
bicarbonate cotransporter polymorphisms are associated with baseline and 10-
year follow-up blood pressures. Hypertension 47: 532–536.
58. Taylor JY, Maddox R, Wu CY (2009) Genetic and environmental risks for high
blood pressure among African American mothers and daughters. Biological
Research For Nursing 11: 53–65.
59. Aqeilan RI, Hassan MQ, de Bruin A, Hagan JP, Volinia S, et al. (2008) The
WWOX tumor suppressor is essential for postnatal survival and normal bone
metabolism. Journal of Biological Chemistry 283: 21629–21639.
Hypertension Susceptibility Genes in Han Chinese
PLoS ONE | www.plosone.org 13 March 2012 | Volume 7 | Issue 3 | e32907
60. Peterson AJ, Mallin DR, Francis NJ, Ketel CS, Stamm J, et al. (2004)
Requirement for sex comb on midleg protein interactions in Drosophila
polycomb group repression. Genetics 167: 1225–1239.
61. Burstein E, Hoberg JE, Wilkinson AS, Rumble JM, Csomos RA, et al. (2005)
COMMD proteins, a novel family of structural and functional homologs of
MURR1. Journal of Biological Chemistry 280: 22222–22232.
62. Wiemuth D, Lott JS, Ly K, Ke Y, Teesdale-Spittle P, et al. (2010) Interaction of
serum- and glucocorticoid regulated kinase 1 (SGK1) with the WW-domains of
Nedd4-2 is required for epithelial sodium channel regulation. PLoS One 5:
e12163.
63. Bansal V, Libiger O, Torkamani A, Schork NJ (2010) Statistical analysis
strategies for association studies involving rare variants. Nature Reviews
Genetics 11: 773–785.
64. Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, et al. (2003) Mice deficient
in alpha-actinin-4 have severe glomerular disease. The Journal of Clinical
Investigation 111: 1683–1690.
65. Jakobsson J, Karypidis H, Johansson JE, Roh HK, Rane A, et al. (2004) A
functional C-G polymorphism in the CYP7B1 promoter region and its different
distribution in Orientals and Caucasians. The Pharmacogenomics Journal 4:
245–250.
66. Li-Hawkins J, Lund EG, Turley SD, Russell DW (2000) Disruption of the
oxysterol 7alpha-hydroxylase gene in mice. Journal of Biological Chemistry 275:
16536–16542.
67. Hanasaki H, Takemura Y, Fukuo K, Ohishi M, Onishi M, et al. (2009) Fas
promoter region gene polymorphism is associated with an increased risk for
myocardial infarction. Hypertension Research 32: 261–264.
68. Zhang MC, Furukawa H, Tokunaka K, Saiga K, Date F, et al. (2008) Mast cell
hyperplasia in the skin of Dsg4-deficient hypotrichosis mice, which are long-
living mutants of lupus-prone mice. Immunogenetics 60: 599–607.
69. Pineda LL, Nakano A, Iijima M, Wada M, Yamasaki Y, et al. (2003) A new
mutation, ataxia and male sterility (ams), of autoimmune-prone MRL/lpr mouse
is not linked to lpr gene but associated with reduction of spleen size and
alteration of lymphocyte subpopulations. Pathology International 53: 390–395.
70. Cooney GJ, Lyons RJ, Crew AJ, Jensen TE, Molero JC, et al. (2004) Improved
glucose homeostasis and enhanced insulin signalling in Grb14-deficient mice.
EMBO Journal 23: 582–593.
71. Goenaga D, Hampe C, Carre N, Cailliau K, Browaeys-Poly E, et al. (2009)
Molecular determinants of Grb14-mediated inhibition of insulin signaling.
Molecular Endocrinology 23: 1043–1051.
72. Wang K, Li WD, Zhang CK, Wang ZH, Glessner JT, et al. (2011) A Genome-
Wide Association Study on Obesity and Obesity-Related Traits. PLoS ONE 6.
73. Roy D, Sin SH, Damania B, Dittmer DP (2011) Tumor suppressor genes FHIT
and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood
118: E32–E39.
74. Howie BN, Donnelly P, Marchini J (2009) A flexible and accurate genotype
imputation method for the next generation of genome-wide association studies.
PLoS Genetics 5: e1000529.
75. Buil A, Martinez-Perez A, Perera-Lluna A, Rib L, Caminal P, et al. (2009) A
new gene-based association test for genome-wide association studies. BMC
Proceedings 3: S130.
76. Neale BM, Sham PC (2004) The future of association studies: Gene-based
analysis and replication. American Journal of Human Genetics 75: 353–362.
77. Pan WH, Fann CSJ, Wu JY, Hung YT, Ho MS, et al. (2006) Han Chinese cell
and genome bank in Taiwan: Purpose, design and ethical considerations.
Human Heredity 61: 27–30.
78. The International HapMap Consortium (2003) The International HapMap
Project. Nature 426: 789–796.
79. The International HapMap Consortium (2005) A haplotype map of the human
genome. Nature 437: 1299–1320.
80. The International HapMap Consortium (2004) Integrating ethics and science in
the international HapMap project. Nature Reviews Genetics 5: 467–475.
81. The International HapMap Consortium (2007) A second generation human
haplotype map of over 3.1 million SNPs. Nature 449: 851–861.
82. Puig O, Wang IM, Cheng P, Zhou P, Roy S, et al. (2010) Transcriptome
profiling and network analysis of genetically hypertensive mice identifies
potential pharmacological targets of hypertension. Physiological Genomics 42:
24–32.
83. Guo SW, Thompson EA (1992) Performing the exact test of Hardy-Weinberg
proportion for multiple alleles. Biometrics 48: 361–372.
84. Devlin B, Roeder K (1999) Genomic control for association studies. Biometrics
55: 997–1004.
85. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006)
Principal components analysis corrects for stratification in genome-wide
association studies. Nature Genetics 38: 904–909.
86. Wilcoxon F (1945) Individual comparisons by ranking methods. Biometrics
Bulletin 1: 80–83.
87. Riva A, Kohane IS (2004) A SNP-centric database for the investigation of the
human genome. BMC Bioinformatics 5: 33.
88. Zaykin DV, Zhivotovsky LA, Westfall PH, Weir BS (2002) Truncated product
method for combining P-values. Genetic Epidemiology 22: 170–185.
89. Yang HC, Hsieh HY, Fann CSJ (2008) Kernel-based association test. Genetics
179: 1057–1068.
90. Yang HC, Lin CY, Fann CSJ (2006) A sliding-window weighted linkage
disequilibrium test. Genetic Epidemiology 30: 531–545.
91. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical
and powerful approach to multiple testing. Journal of the Royal Statistical
Society Series B-Methodological 57: 289–300.
92. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of
normalization methods for high density oligonucleotide array data based on
variance and bias. Bioinformatics 19: 185–193.
93. Kendall MG (1938) A new measure of rank correlation. Biometrika 30: 81–93.
94. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, et al. (2009)
Common regulatory variation impacts gene expression in a cell type-dependent
manner. Science 325: 1246–1250.
95. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, et al. (2011) The architecture of
gene regulatory variation across multiple human tissues: the MuTHER study.
PLoS Genetics 7: e1002003.
96. Horvath S, Laird NM (1998) A discordant-sibship test for disequilibrium and
linkage: No need for parental data. American Journal of Human Genetics 63:
1886–1897.
97. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, et al. (2007)
PLINK: A tool set for whole-genome association and population-based linkage
analyses. American Journal of Human Genetics 81: 559–575.
Hypertension Susceptibility Genes in Han Chinese
PLoS ONE | www.plosone.org 14 March 2012 | Volume 7 | Issue 3 | e32907
